How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

344 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

65. Tropical Travel Trouble 009 Humongous HIV Extravaganza

) or Cobicistat is frequently used, The small “r” depicted as a ‘r’ on the end of the 3 letter abbreviations for drugs used can signal ritonavir (i.e. DRV/r) Atazanavir (ATV) Darunavir (DRV) Fos-Amprenavir Lopinavir (LPV) Saquinavir (SAQ) Tipranavir (TPV) Integrase Inhibitors. Blocks the viral DNA integrating into the host’s DNA. Raltegravir (RAL) Elvitegravir (EVG) Dolutegravir (DTG) Bictegravir (BIC) Fusion inhibitors: Attachment inhibitors (CCR5): Fixed dose combinations (not a complete list): Dual

2018 Life in the Fast Lane Blog

66. Dyspepsia - proven GORD

efficacy. If concurrent use is necessary, seek specialist advice. Saquinavir — plasma concentration of saquinavir may be increased by PPI treatment, leading to increased risk of adverse effects. Tipranavir — concurrent use with omeprazole or esomeprazole is not recommended, as tipranavir may reduce the plasma concentration of the PPI. If concurrent use is necessary, seek specialist advice. [ ; ] H2-receptor antagonists H2-receptor antagonists Choice of H2-receptor antagonist Choice of H2-receptor

2017 NICE Clinical Knowledge Summaries

67. Dyspepsia - pregnancy-associated

. Tipranavir — the plasma concentration of omeprazole is reduced. Atazanavir — proton pump inhibitors decrease plasma levels. Itraconazole and ketoconazole — proton pump inhibitors decrease absorption of these drugs. Methotrexate — excretion of methotrexate may be reduced with concurrent use of proton pump inhibitors, leading to increased levels and increased risk of toxicity. Inducers of CYP2C19 and CYP3A4 (for example rifampicin and St John's wort) — omeprazole metabolism may be increased by these drugs

2017 NICE Clinical Knowledge Summaries

68. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014. (Full text)

patients with available resistance data during LPV/r treatment, 27(42.3%) carried DRM to protease-inhibitor, 28 (58.3%) to reverse-transcriptase-inhibitors and 21 (43.7%) to non-reverse-transcriptase-inhibitors. Darunavir/ritonavir, atazanavir-ritonavir and tipranavir/ritonavir presented the highest susceptibility and nelfinavir the lowest.A better lymphocyte recovering occurred when protease-inhibitor was taken as part of a first-line regimen and a higher number of patients reached viral suppression

2017 PLoS ONE PubMed

70. Darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza) - HIV Infections

standard deviation SmPC Summary of Product Characteristics SOC system organ class SQV saquinavir TAF tenofovir alafenamide TDF tenofovir disoproxil fumarate TFV tenofovir TFV-DP tenofovir-diphosphate TLOVR time to loss of virologic response tmax actual sampling time to reach the maximum observed analyte concentration TPV tipranavir UGT uridine diphosphate glucuronosyltransferase ULN upper limit of normal UPCR urine protein to creatinine ratio U(H)PLC ultra-high performance liquid chromatography UV

2017 European Medicines Agency - EPARs

74. Hepatitis C (HCV) Cure and Kidney Health

/grazoprevir Co-administration with drugs that are 1) strong CYP3A inducers (e.g., phenytoin, carbamazepine, rifampin); 2) OATP1B1/3 inhibitors (e.g., cyclosporine, darunavir, atazanavir, tipranavir, lopinavir or saquinavir) or 3) efavirenz Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2018 Clinical Trials

75. Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation

, St.John's wort, tenofovir, tipranavir, trazodone, vinblastine) Contraindication to MRI Pregnancy, breast-feeding or having a plan to be pregnant Participation in the other investigational drug trials simultaneously or within 3 months before the first administration of the study medication. Observational studies without an intervention (eg study medication) are allowed. Any clinical conditions (eg abnormal lab tests) unsuitable for undergoing clinical trials at the discretion of the clinical

2018 Clinical Trials

76. 2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. (PubMed)

and the addition of maraviroc, tipranavir and elvitegravir to the system.The no-genotype models achieved area under the receiver operator characteristic curve (AUC) values of 0.82 and 0.81 using the standard and relaxed baseline data windows, respectively. The genotype models achieved AUC values of 0.86 with the new non-adherence filter and 0.84 without. Both sets of models were significantly more accurate than genotyping with rules-based interpretation, which achieved AUC values of only 0.55-0.63, and were

2018 Journal of Antimicrobial Chemotherapy

77. Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African Am

) Efavirenz (EFV) Nevirapine (NVP) Rilpivirine (RPV) Integrase inhibitors Dolutegravir (DTG) Elvitegravir (EVG) Raltegravir (RAL) Protease inhibitors (PIs) Atazanavir (ATV) Darunavir (DRV) Lopinavir Nelfinavir NFV) Saquinavir (SQV) Tipranavir (TPV) Third agents will be administered as prescribed without regard to food. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. Outcome Measures Go to Primary Outcome Measures : Proportion

2018 Clinical Trials

78. Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

, saquinavir, or tipranavir; Corticosteroids, either systemically, inhaled, intranasally, orally, or by intra-articular injection within 14 days before the study surgical procedure (topical corticosteroid is allowed); Non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to the study surgical procedure; Any investigational product within 30 days prior to administration of blinded study medication. History of alcohol abuse or prescription and/or illicit drug abuse within 2 years prior

2018 Clinical Trials

79. Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients

, carbamazepine, St. John's Wort, efavirenz, neivrapine, etravirine, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, cobicistat Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT03713645 Contacts Layout

2018 Clinical Trials

80. Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap–Core Interface of HIV-1 Protease (Full text)

Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap–Core Interface of HIV-1 Protease Four HIV-1 protease (PR) inhibitors, clinical inhibitors lopinavir and tipranavir, and two investigational compounds 4 and 5, were studied for their effect on the structure and activity of PR with drug-resistant mutation L76V (PRL76V). Compound 5 exhibited the best Ki value of 1.9 nM for PRL76V, whereas the other three inhibitors had Ki values of 4.5-7.6 nM, 2-3 orders of magnitude worse

2018 ACS Omega PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>